Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity

- Serum soluble Talin-1 (sTalin-1) levels were significantly higher in MS than normal controls (NCs).
- The serum sTalin-1 levels were associated with a sustained increase in disability after an MS attack.
- sTalin-1 may be a biomarker for the acute phase of MS and a therapeutic target for MS.

Previously, we identified anti-Talin-1 antibodies in the serum of MS. In this case, we measured the serum soluble Talin-1 (sTalin-1) levels by enzyme-linked immunosorbent assay. The serum sTalin-1 levels were significantly higher in 40 patients with MS than in 43 normal controls and in the acute phase of disease than in the remission phase. Interestingly, serum sTalin-1 levels were associated with a sustained increase in disability after MS attack but not with serum anti-Talin-1 antibody levels. sTalin-1 may be a biomarker for the acute phase of MS and may be used for the short-term prognosis of MS.

81